Prostate cancer management

Annals of Oncology

Volumn 15, Issue SUPPL. 4, 2004, Pages

  Horwich, A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CANCER VACCINE; CAPECITABINE; CLODRONIC ACID; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; ESTRAMUSTINE; ESTROGEN; FINASTERIDE; GONADORELIN AGONIST; HORMONE; MITOXANTRONE; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; SELENIUM; STRONTIUM 89; TAXANE DERIVATIVE; THALIDOMIDE; ZOLEDRONIC ACID;

ARTICLE; BLEEDING; BLOOD VESSEL COMPLIANCE; BONE METABOLISM; BONE METASTASIS; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CARDIOTOXICITY; CLINICAL TRIAL; EARLY CANCER; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HISTORY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; META ANALYSIS; METASTASIS; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECTUM INJURY; SEXUAL DYSFUNCTION; SIDE EFFECT; THROMBOEMBOLISM;

EID: 9744243458     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh944     Document Type: Article

References (38)

1. Sakr WA, Grignon DJ, Crissman JD et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994; 8: 439-443.
2. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
3. Albertsen P, Gleason D, Barry M. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-980.
4. Harisinghani MG, Barentsz J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-2499.
5. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395-406.
6. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-1451.
7. Parker C. Why the PSA test is not currently suitable for screening all men. CancerBACUP News 2002; 45: 5.
8. Steineck G, Bergmark K, Henningsohn L et al. Symptom documentation in cancer survivors as a basis for therapy modifications. Acta Oncol 2002; 41: 244-252.
9. Choo R, Hruby G, Hong J et al. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable post-operative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys 2002; 52: 674-680.
10. Walsh P. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000; 163: 1802-1807.
11. Madalinska JB, Essink-Bot ML, de Koning HJ et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001; 19: 1619-1628.
12. Potosky AL, Legler J, Albertsen PC et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92: 1582-1592.
13. Morgan WR, Bergstalh EJ, Zincke H. Long-term evaluation of radical prostatectomy for clinical stage C (T3) prostate cancer. Urology 1993; 41: 113-117.
14. Steiner MS. High grade prostatic intraepithelial neoplasia is a disease. Curr Urol Rep 2001; 2: 195-198.
15. Lu-Yao G, Yao S. Population-based study of long-term survival in patients with clinically localised prostate cancer (see comments). Lancet 1997; 349: 906-910.
16. Zelefsky MJ, Cowen D, Fuks Z et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85: 2460-2468.
17. Dearnaley D, Norman A, Shahidi M. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study. J Urol 1999; 162: 170.
18. Pollack A, Zagars GK, Smith LG et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000; 18: 3904-3911.
19. Nutting CM, Convery DJ, Cosgrove VP et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2000; 48: 649-656.
20. Hanks G, Lu JD, Machtay M et al. RTOG PROTOCOL 92-02: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2000; 48 (Suppl 1): 112 (Abstr 4).
21. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin (see comments). N Engl J Med 1997; 337: 295-300.
22. Roach M 3rd, DeSilvio M, Lawton C et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-1911.
23. Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-1582.
24. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-269.
25. Medical Research Council Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235-246.
26. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitroxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomised trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
27. Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 2000; 27 (2 Suppl 3): 24-29.
28. Eisenberger M, De Wit R, Berry W et al. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2004; (Abstr 4).
29. Petrylak D, Tangen P, Hussain M et al. SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustin (E) versus mitoxantrone (M)/prednisone (p) in men with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol 2004; 23: 2 (Abstr 3).
30. Vaishampayan U, Fontana J, Du W, Hussain M. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. Urology 2002; 60: 1050-1054.
31. Beer TM, Eilers KM, Garzotto M et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21: 123-128.
32. Gulley J, Dahut W. Novel clinical trials in androgen-independent prostate cancer. Clin Prostate Cancer 2002; 1: 51-57.
33. Figg WD, Kruger EA, Price DK et al. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 2002; 20: 183-194.
34. Carducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679-689.
35. Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomised controlled trial. Semin Oncol 1993; 20 (3 Suppl 2): 38-43.
36. Lipton A, Small E, Saad F et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20 (Suppl 2): 45-54.
37. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
38. Ernst DS, Tannock IF, Winquist EW et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003; 21: 3335-3342.